Related Experiment Video
Updated: Oct 25, 2025
11:58
Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
38.6K
Where Dopaminergic and Cholinergic Systems Interact: A Gateway for Tuning Neurodegenerative Disorders.
Marianne Amalric1, Tommy Pattij2, Ioannis Sotiropoulos3,4
1Centre National de la Recherche Scientifique (CNRS), UMR 7291, Laboratoire de Neurosciences Cognitives, Aix-Marseille University (AMU), Marseille, France.
Frontiers in Behavioral Neuroscience
|August 9, 2021
Summary
Neurodegenerative diseases like Parkinson's and Alzheimer's involve complex brain circuit interactions. Research explores cholinergic and dopaminergic systems, stress, and novel drug delivery for new treatments.
Area of Science:
- Neuroscience
- Behavioral Pharmacology
- Cellular Neuroscience
Background:
- Neurodegenerative diseases (NDs) like Parkinson's (PD) and Alzheimer's (AD) involve neuronal circuit dysfunction, not just single cell loss.
- Dopaminergic and cholinergic systems are critical for cognitive and motor functions affected in PD and AD.
- Understanding circuit interactions offers new therapeutic avenues for NDs.
Purpose of the Study:
- To update on recent work investigating cholinergic-dopaminergic interactions in PD models.
- To examine the role of stress in Alzheimer's disease pathogenesis.
- To present novel approaches for brain drug delivery.
Main Methods:
- Behavioral and cellular neuroscience techniques.
- Modeling of Parkinson's disease.
- Investigation of stress mechanisms in Alzheimer's disease.
- Development of implantable cell-based drug delivery systems.
Main Results:
- Striatal cholinergic interneurons (CINs) are implicated in PD.
- Cholinergic and dopaminergic systems modulate impulse control.
- Implantable systems show potential for targeted brain drug delivery.
- Daily life stress disrupts protein and RNA homeostasis, contributing to AD.
Conclusions:
- Interactions between cholinergic and dopaminergic systems are crucial in neurodegeneration.
- Stress is a significant factor in Alzheimer's disease pathology.
- Advanced drug delivery methods are being developed for brain disorders.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
1.7K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.7K
01:15Parkinson's Disease: Overview
990
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
990
01:26Neurochemical Transmission: Sites of Drug Action
3.0K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.0K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.0K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.0K
01:23Cholinergic Neurons: Neurotransmission
4.4K
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
4.4K
01:29Excitatory and Inhibitory Effects of Neurotransmitters
11.5K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
11.5K